北美乳腺癌治疗市场预测至 2030 年 - 区域分析 - 按药物治疗 [靶向药物治疗(Abemaciclib、Ado-Trastuzumab Emtansine、Palbociclib、曲妥珠单抗和其他靶向药物治疗)、激素药物治疗(选择性雌激素受体调节剂、芳香酶抑制剂) 、选择性雌激素受体下调剂)、化疗、免疫治疗/生物治疗]、乳腺癌类型(激素受体、HER2+、三阴性乳腺癌)、分销渠道(医院药房、药店和零售药房、网上药房) )

Historic Data: 2020-2021   |   Base Year: 2022   |   Forecast Period: 2023-2030


No. of Pages: 94    |    Report Code: BMIRE00029747    |    Category: Life Sciences

North America Breast Cancer Therapeutics Market
2022年北美乳腺癌治疗市场价值为133.4687亿美元,预计到2030年将达到270.1492亿美元;预计 2022 年至 2030 年复合年增长率为 9.2%。

个性化医疗的使用不断增加推动北美乳腺癌治疗市场

个性化医疗涉及为个体患者量身定制治疗计划除其他因素外,还基于其基因构成。这种方法考虑到每个患者癌症的独特特征,因此可以实现高度针对性和有效的治疗。基因组学和分子诊断的进步使个性化医疗成为乳腺癌治疗的可行选择。医疗保健提供者可以通过在分子水平上分析患者的肿瘤来识别驱动癌症生长的特定基因突变或生物标志物。然后可以使用该信息来选择最合适的治疗方案,例如可能对特定患者最有效的靶向疗法或免疫疗法。在乳腺癌治疗中使用个性化医疗有可能显着改善患者的治疗效果。例如,2022 年 2 月,NIH 研究人员开发了一种个性化乳腺癌治疗方法,这是一种实验形式的免疫疗法,使用患者的抗肿瘤免疫细胞来治疗转移性乳腺癌患者,从而推进个性化医疗。

通过为个体患者提供量身定制的治疗,医疗保健提供者可以增加成功结果的可能性并降低不必要的副作用的风险。除了改善患者的治疗效果外,个性化医疗还可以带来经济效益。通过选择更有可能有效的治疗方法,医疗保健提供者可以减少与无效治疗相关的医疗费用,并避免不必要的费用。随着基因组学和分子诊断的进步,个性化医疗可能会在未来几年变得越来越容易获得并融入标准治疗方案。因此,个性化医疗的日益普及预计将为北美乳腺癌治疗市场带来新的增长趋势。

北美乳腺癌治疗市场概述

北美乳腺癌治疗市场分为美国、加拿大和墨西哥;美国在该地区占有最大的市场份额。市场增长主要归因于该地区,由于乳腺癌患病率上升以及开发新疗法的研发投资增加等因素,预计该地区将持续增长。此外,越来越多的市场参与者正在扩大其在北美国家的地理足迹。

医疗技术和研究的进步引发了突破性治疗方法的诞生,可以改善患者的治疗效果。辉瑞(Pfizer)、诺华(Novartis)、罗氏(Roche)、阿斯利康(AstraZeneca)和礼来(Eli Lilly)等几家大型制药公司主导了美国乳腺癌治疗市场。这些企业在研发方面进行了大量投资,以向市场推出新型和增强型药物。政府制定的法规和政策也会影响市场。用于乳腺癌治疗的新药物和疗法已获得美国食品和药物管理局 (FDA) 政府机构的批准。未来几年,乳腺癌的治疗市场预计将进一步扩大。

北美乳腺癌治疗市场收入和预测到 2030 年(百万美元)

北美乳腺癌治疗市场细分

北美乳腺癌治疗市场已细分基于药物治疗、乳腺癌类型和分销渠道。

根据药物治疗,北美乳腺癌治疗市场分为靶向药物治疗、激素药物治疗、化疗和免疫治疗/生物治疗。 2022年,靶向药物治疗细分市场将占据更大份额。靶向药物治疗细分市场进一步细分为abemaciclib、ado-trastuzumab emtansine、palbociclib、trastuzumab和其他靶向药物治疗。此外,激素药物治疗部分分为选择性雌激素受体调节剂、芳香酶抑制剂和选择性雌激素受体下调剂。

就乳腺癌类型而言,北美乳腺癌治疗市场分为激素受体乳腺癌、HER2+乳腺癌和三阴性乳腺癌。激素受体细分市场在 2022 年将占据更大份额。

按分销渠道,北美乳腺癌治疗市场分为医院药房、药店和零售药房以及在线药房。到 2022 年,医院药房细分市场将占据更大的份额。

按国家/地区划分,北美乳腺癌治疗市场分为美国、加拿大和墨西哥。 2022 年,美国将主导北美乳腺癌治疗市场。

礼来公司、卫材有限公司、诺华公司、阿斯利康公司、辉瑞公司、吉利德科学公司、默克公司、基因泰克公司、梯瓦制药Pharmaceutical Industries Ltd 和 Amgen Inc 是北美乳腺癌治疗市场上的一些领先公司。

North America Breast Cancer Therapeutics Strategic Insights

Strategic insights for North America Breast Cancer Therapeutics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/north-america-breast-cancer-therapeutics-market-strategic-framework.webp
Get more information on this report

North America Breast Cancer Therapeutics Report Scope

Report Attribute Details
Market size in 2022 US$ 13,346.87 Million
Market Size by 2030 US$ 27,014.92 Million
Global CAGR (2022 - 2030) 9.2%
Historical Data 2020-2021
Forecast period 2023-2030
Segments Covered By 药物治疗
  • 靶向药物治疗
  • 激素药物治疗
  • 化疗
  • 免疫治疗/生物治疗
By 乳腺癌类型
  • 激素受体
  • HER2+
  • 三阴性乳腺癌
By 分销渠道
  • 医院药房
  • 药店和零售药房
  • 网上药房
Regions and Countries Covered 北美
  • 美国
  • 加拿大
  • 墨西哥
Market leaders and key company profiles
  • Eli Lilly and Co
  • Eisai Co Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Pfizer Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Genentech Inc
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc
  • Get more information on this report

    North America Breast Cancer Therapeutics Regional Insights

    The regional scope of North America Breast Cancer Therapeutics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/north-america-breast-cancer-therapeutics-market-geography.webp
    Get more information on this report

    The List of Companies - North America Breast Cancer Therapeutics Market

    1. Eli Lilly and Co
    2. Eisai Co Ltd
    3. Novartis AG
    4. AstraZeneca Plc
    5. Pfizer Inc
    6. Gilead Sciences Inc
    7. Merck & Co Inc
    8. Genentech Inc
    9. Teva Pharmaceutical Industries Ltd
    10. Amgen Inc

    Frequently Asked Questions
    How big is the North America Breast Cancer Therapeutics Market?

    The North America Breast Cancer Therapeutics Market is valued at US$ 13,346.87 Million in 2022, it is projected to reach US$ 27,014.92 Million by 2030.

    What is the CAGR for North America Breast Cancer Therapeutics Market by (2022 - 2030)?

    As per our report North America Breast Cancer Therapeutics Market, the market size is valued at US$ 13,346.87 Million in 2022, projecting it to reach US$ 27,014.92 Million by 2030. This translates to a CAGR of approximately 9.2% during the forecast period.

    What segments are covered in this report?

    The North America Breast Cancer Therapeutics Market report typically cover these key segments-

  • 药物治疗 (靶向药物治疗, 激素药物治疗, 化疗, 免疫治疗/生物治疗)
  • 乳腺癌类型 (激素受体, HER2+, 三阴性乳腺癌)
  • 分销渠道 (医院药房, 药店和零售药房, 网上药房)
  • What is the historic period, base year, and forecast period taken for North America Breast Cancer Therapeutics Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Breast Cancer Therapeutics Market report:

  • Historic Period : 2020-2021
  • Base Year : 2022
  • Forecast Period : 2023-2030
  • Who are the major players in North America Breast Cancer Therapeutics Market?

    The North America Breast Cancer Therapeutics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Eli Lilly and Co
  • Eisai Co Ltd
  • Novartis AG
  • AstraZeneca Plc
  • Pfizer Inc
  • Gilead Sciences Inc
  • Merck & Co Inc
  • Genentech Inc
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc
  • Who should buy this report?

    The North America Breast Cancer Therapeutics Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the North America Breast Cancer Therapeutics Market value chain can benefit from the information contained in a comprehensive market report.